Condition: T2DM (Type 2 Diabetes Mellitus) · Dyslipidemias · Sponsor: Korea University Anam Hospital
The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration
This description comes directly from the study's public registry record.
SIN-GON KIM · 8229205890 · k50367@korea.ac.kr
Always discuss trial participation with your own doctor first.
| Korea University Anam Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06293417